Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Jul 9, 2022; 11(4): 341-350
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.341
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.341
Prevalence, phenotype and medication for the pediatric inflammatory bowel disease population of a state in Southeastern Brazil
Adalberta Lima Martins, Pharmaceutical Assistance, Health Department of Espírito Santo, Vitoria 29052-210, Espírito Santo, Brazil
Renata de Sá Brito Fróes, Department of Gastroenterology, Gastromed, Rio de Janeiro 22640-100, Rio de Janeiro, Brazil
Maria da Penha Zago-Gomes, Departament of Medical Clinical, Hospital Universitário Cassiano Antonio Moraes, Vitoria 29042-755, Espírito Santo, Brazil
Author contributions: Martins AL contributed to concept, design of the research, collection of the data, analysis, interpretation, and writing; Fróes RSB contributed to interpretation, writing and review; Zago-Gomes MP contributed to analyses study, statistical analysis, interpretation, and writing.
Institutional review board statement: This study was approved by the Ethics and Research Committee of the Nossa Senhora da Gloria Children’s Hospital (CAAE 19602813.8.0000.5069) after obtaining authorization from the State Office for Pharmaceutical Assistance. The term of clarification and consent was waived because the data used is secondary data.
Informed consent statement: The terms of clarification and responsibility were not necessary because the information used were secondary data from Espírito Santo's State Health Department documents.
Conflict-of-interest statement: All the authors have no conflicts of interest to disclose related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Adalberta Lima Martins, MSc, Doctor, Pharmaceutical Assistance, Health Department of Espírito Santo, Desembargador Ferreira Coelho 330/315 Praia do Suá, Ed. Eldorado, Vitoria 29052-210, Espírito Santo, Brazil. limambeta@uol.com.br
Received: January 7, 2022
Peer-review started: January 7, 2022
First decision: March 9, 2022
Revised: March 23, 2022
Accepted: June 3, 2022
Article in press: June 3, 2022
Published online: July 9, 2022
Peer-review started: January 7, 2022
First decision: March 9, 2022
Revised: March 23, 2022
Accepted: June 3, 2022
Article in press: June 3, 2022
Published online: July 9, 2022
Core Tip
Core Tip: In Brazil, where the prevalence of inflammatory bowel disease (IBD) in adults is increasing, the epidemiology of the pediatric population is not well known, although there is a documented increase in pediatric IBD incidence worldwide. Espírito Santo is a state of southeastern Brazil, the region with the highest demographic densities and that is the economically most important in the country. Our epidemiological data, including behavior and medication, evaluate the comparison between the pediatric and adult age groups. Therefore, this study has the potential to reinforce the need for adequate care of pediatric patients with IBD, with the potential to influence public health policies.